All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Is mini-hyper-CVD plus venetoclax safe and effective in patients with R/R Ph- ALL?
Bookmark this article
During the 2023 European Hematology Association (EHA) Congress, the ALL Hub spoke to Fadi Haddad, MD Anderson Cancer Center, US. We asked, is mini-hyper-CVD plus venetoclax safe and effective in patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL)?
Is mini-hyper-CVD plus venetoclax safe and effective in patients with R/R Ph- ALL?
Haddad provided the rationale for this study by highlighting the synergistic effects and promising activity of the BCL2 inhibitor venetoclax plus chemotherapy in pre-clinical studies, as well as in patients with R/R ALL. This phase II trial included patients with R/R B-cell or T-cell ALL who received a median of two prior lines of therapy and had poor risk cytogenetics. Study endpoints included the safety profile, response rates, and survival outcomes.
Haddad concluded that mini-hyper-CVD plus venetoclax proved clinically effective and safe in patients with R/R Ph-ALL and, while it is not a definitive combination therapy, it could serve as a potential bridging therapy to stem cell transplantation or other therapies.
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox